Fimasartan, a novel angiotensin II receptor antagonist.

Article Details

Citation

Copy to clipboard

Kim JH, Lee JH, Paik SH, Kim JH, Chi YH

Fimasartan, a novel angiotensin II receptor antagonist.

Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z.

PubMed ID

22864732 [ View in PubMed

]

Abstract

Fimasartan (Kanarb(R)), an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound that was developed by Boryung Pharm. Co., Ltd. Among numerous synthetic derivatives, fimasartan was chosen as a new drug candidate through in vitro and in vivo screening studies. Pharmadynamic-pharmacokinetic properties and safety profiles were determined in a series of nonclinical and clinical studies. Fimasartan is a new angiotensin receptor blocker, and the first new molecular entity acting on cardiovascular system approved by Korean Food and Drug Administration for the treatment of essential hypertension in September 2010. Further development process for combination therapy and overseas registration is currently ongoing.

DrugBank Data that Cites this Article

Drugs

Fimasartan

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Fimasartan	Type-1 angiotensin II receptor	Protein	Humans	Yes	Antagonist	Details